JP5779503B2 - 酸化ストレスを用いるレトロウイルスレゼルボアの処置 - Google Patents

酸化ストレスを用いるレトロウイルスレゼルボアの処置 Download PDF

Info

Publication number
JP5779503B2
JP5779503B2 JP2011533630A JP2011533630A JP5779503B2 JP 5779503 B2 JP5779503 B2 JP 5779503B2 JP 2011533630 A JP2011533630 A JP 2011533630A JP 2011533630 A JP2011533630 A JP 2011533630A JP 5779503 B2 JP5779503 B2 JP 5779503B2
Authority
JP
Japan
Prior art keywords
hiv
cells
auranofin
hdaci
bso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011533630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506884A (ja
JP2012506884A5 (enExample
Inventor
サバリノ，アンドレア
ルシク，マリナ
マイ，アントネジョ
パラマラ，アンナ，テレサ
ガラチ，エンリコ
Original Assignee
イスティチュート スペリオーレ ディ サニータ
イスティチュート スペリオーレ ディ サニータ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0819857A external-priority patent/GB0819857D0/en
Priority claimed from GB0908952A external-priority patent/GB0908952D0/en
Application filed by イスティチュート スペリオーレ ディ サニータ, イスティチュート スペリオーレ ディ サニータ filed Critical イスティチュート スペリオーレ ディ サニータ
Publication of JP2012506884A publication Critical patent/JP2012506884A/ja
Publication of JP2012506884A5 publication Critical patent/JP2012506884A5/ja
Application granted granted Critical
Publication of JP5779503B2 publication Critical patent/JP5779503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011533630A 2008-10-29 2009-10-29 酸化ストレスを用いるレトロウイルスレゼルボアの処置 Active JP5779503B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0819857.4 2008-10-29
GB0819857A GB0819857D0 (en) 2008-10-29 2008-10-29 Antiviral therapy
GB0908952.5 2009-05-22
GB0908952A GB0908952D0 (en) 2009-05-22 2009-05-22 Antiviral therapy
PCT/EP2009/007958 WO2010049182A2 (en) 2008-10-29 2009-10-29 Treatment of retroviral reservoirs exploiting oxidative stress

Publications (3)

Publication Number Publication Date
JP2012506884A JP2012506884A (ja) 2012-03-22
JP2012506884A5 JP2012506884A5 (enExample) 2012-12-13
JP5779503B2 true JP5779503B2 (ja) 2015-09-16

Family

ID=41596151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533630A Active JP5779503B2 (ja) 2008-10-29 2009-10-29 酸化ストレスを用いるレトロウイルスレゼルボアの処置

Country Status (6)

Country Link
US (3) US8785493B2 (enExample)
EP (1) EP2349245B1 (enExample)
JP (1) JP5779503B2 (enExample)
ES (1) ES2600789T3 (enExample)
PL (1) PL2349245T3 (enExample)
WO (1) WO2010049182A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
US9719069B2 (en) 2009-01-27 2017-08-01 University Of Utah Research Foundation Methods and compositions relating to viral latency
GB201011921D0 (en) * 2010-07-15 2010-09-01 Sutan Anwar Method for gas chromatography analysis and maintenance
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102727523A (zh) * 2011-04-02 2012-10-17 复旦大学 一种具有抗hiv潜伏作用的药物及其用途
KR20150132345A (ko) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac 저해제
EP3008043A2 (en) * 2013-06-14 2016-04-20 University Of Utah Research Foundation Triazol-1-ol analogs anti-retroviral latency drugs
EP3470536A1 (en) * 2013-10-01 2019-04-17 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
US12220420B2 (en) * 2016-05-03 2025-02-11 Galera Labs, Llc Combination therapy for cancer treatment
BR112019019491A2 (pt) 2017-03-23 2020-04-22 Istituto Superiore di Sanità sulfoximina butionina e um metalofármaco para tratamento de câncer, hiv ou uma doença reumática
US20230285441A1 (en) * 2020-04-15 2023-09-14 Georgia State University Research Foundation, Inc. Treatment of coronavirus infections with auranofin
CN116478070B (zh) * 2022-06-23 2024-09-27 山东第一医科大学(山东省医学科学院) 一种化合物、药物组合物及其在扩张血管或抗病毒领域的应用
CN116947763A (zh) * 2023-07-11 2023-10-27 郑州大学 2-巯基-5-氰基-6-芳基嘧啶杂环类化合物、制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232685B2 (en) * 2001-12-19 2007-06-19 The Regents Of The Universtiy Of California Cell lines with latent immunodeficiency virus and methods of use thereof
AU2002351898A1 (en) * 2001-12-21 2003-07-09 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US8247613B2 (en) * 2006-04-17 2012-08-21 The J. David Gladstone Institutes Methods and compositions for the synergistic activation of latent HIV

Also Published As

Publication number Publication date
JP2012506884A (ja) 2012-03-22
PL2349245T3 (pl) 2017-07-31
US8785493B2 (en) 2014-07-22
US20150024065A1 (en) 2015-01-22
US20110305774A1 (en) 2011-12-15
WO2010049182A2 (en) 2010-05-06
US20170157174A1 (en) 2017-06-08
EP2349245B1 (en) 2016-08-03
ES2600789T3 (es) 2017-02-10
WO2010049182A3 (en) 2010-12-02
EP2349245A2 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
JP5779503B2 (ja) 酸化ストレスを用いるレトロウイルスレゼルボアの処置
US12083119B2 (en) Methods and compositions for treating viral or virally-induced conditions
US6803379B2 (en) Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
Hess-Stumpp Histone deacetylase inhibitors and cancer: from cell biology to the clinic
EP3054953B1 (en) Hdac inhibitors in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
Mei et al. Role of histone deacetylase inhibitors in the treatment of cancer
EP3166603B1 (en) Treatment of leukemia with histone deacetylase inhibitors
Pham et al. Research of novel anticancer agents targeting arginase inhibition
EP3054954A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
Wang et al. Antitumor activity of Chidamide in hepatocellular carcinoma cell lines
AU2015356779A1 (en) Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
Takai et al. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis
Nadhan et al. Perspectives on mechanistic implications of ROS inducers for targeting viral infections
US20160213669A1 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
Garg et al. Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells
Karam et al. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models
Qu et al. Histone deacetylase inhibitor MC1293 induces latent HIV-1 reactivation by histone modification in vitro latency cell lines
Vandergeeten et al. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-α+ TSA
EP2908821A1 (en) Treatment of viral and infectious diseases using an inhibitor of cbp/catenin
US20190290621A1 (en) Compositions and methods for treating hiv-1 latency
WO2015009879A1 (en) Compositions for modulating nrf2-are activity and their methods of use
US20240109852A1 (en) Ferroptosis-HDAC Inhibitor Hybrid Anticancer Agents
Ververis et al. The potential role of HDAC inhibitors in de-silencing latent HIV virus
Prakash Effects of heme arginate in HIV-1 acute infection and in latency reversal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140430

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150318

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150713

R150 Certificate of patent or registration of utility model

Ref document number: 5779503

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250